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S228 Poster Session Iwho completed three psychometric instruments prior to priming for
stem cell collection and at approximately day 42 post ASCT. The
three instruments are the Functional Assessment of Cancer Therapy
– Bone Marrow Transplant (FACT-BMT), measuring quality of life;
Brief COPE, measuring coping with illness; and Profile of Mood
States (POMS) short form, measuring mood states.
In comparisons of patient and transplant characteristics including
(but not limited to) gender, race, diagnosis, length of stay, and read-
missions, the following significant differences were found between
patients 60+ and under 60 years of age: Patients 60+ had a slightly
longer length of stay (median 21 vs. 20 days, p5 0.013), were
more likely to have NHL (75% vs. 61%), and less likely to have
Hodgkins (2% vs.19%, p\0.001).
Many significant differences were found in quality of life scores
between patients 60+ and under 60. Patients 60+ reported better so-
cial, emotional, and functional well-being at both pre-transplant and
at day 42 post-transplant (p# 0.05). The 60+ group also reported
better physical well-being at pre-transplant compared to the under
60 group (p5 0.022). Regarding significant differences in coping,
the 60+ group used less coping techniques of self-distraction, behav-
ioral disengagement, venting, planning, humor, and self-blame, but
reported more acceptance in coping with illness (p# 0.05). There are
four significant differences between the two groups on mood states
but only at pre-transplant. The 60+ group reports less depression,
anger, tension, and confusion than the under 60 group (p# 0.05).
It is surprising patients over 60 report better quality of life, better
mood states, and less utilization of coping techniques. It seems
that older patients are more accepting of illness and impact on func-
tioning, perceive themselves as not needing as much support to cope,
and report less negative impact on mood states than their younger
counterparts.188
LONG-TERM FOLLOW-UP AFTER ALLOGENEIC HEMATOPOIETIC PRO-
GENITOR CELL TRANSPLANTATION IN PEDIATRIC PATIENTS-MULTICEN-
TER STUDY
Gorczynska, E.1, Dyla, A.1, Owoc-Lempch, J.1, Musial, J.1,
Turkiewicz, D.1, Kalwak, K.1, Ussowicz, M.1, Chybicka, A.1,
Pieczonka, A.2, Jacek, W.2, Wojcik, B.3, Kowalczyk, J.3 1Wroclaw Med-
ical University, Wroclaw, Poland; 2University of Medical Sciences,
Poznan, Poland; 3Medical University, Lublin, Poland
Hematopoietic progenitor cell transplantation (HPCT) remains
a salvage therapy for both malignant and non-malignant disorders.
However, it may result in late sequelae which negatively influence
the quality of life. The aim of this study was to evaluate the long-
term impact of HPCT on the patients’ health status. Two hundred
thirty one patients, who survived over one year after allogeneic
HPCT were included into the study. The median age at HPCT
was 11.5 years (from 4 months to 18 years), the median follow-up pe-
riod was 3.5 years (from 13 months to 12 years). One hundred eighty
three subjects were transplanted due to malignant diseases (group I)
and forty eight due to non-malignant disorders (group II). The fre-
quency of late side effects, including chronic Graft-versus-Host Dis-
ease (GvHD), endocrinal dysfunctions and organs impairment, were
compared between two groups using chi2 test.
Only 65 (28.1%) patients in the study group did not suffer from
any health problems. During the follow-up 15 (8.2%) patients in
group I died due to late complications (6 cGvHD, 5 infections, 2 sec-
ond neoplasm, 1 pulmonary artery thrombosis, 1 haemorrhage). In
group II two (4.2%) patients died (1 cGvHD, 1 haemorrhage),
p5 0.34. The incidence of late sequelae in group I and II was docu-
mented respectively: cGvHD 86 (47%) vs 10 (20.8%), p5 0.001; oc-
ular complications 39 (21.3%) vs 4 (8.3%), p5 0.04; skin problems
69 (37.7%) vs 6 (12.5%), p5 0.0009; hormonal dysfunction 64
(35%) vs 19 (39.6%), p5 0.55; pulmonary complications 55 (30%)
vs 9 (18.7%), p5 0.12; bone and joint impairment 32 (17.5%) vs 4
(8.3%), p5 0.12; cardiological dysfunction 25 (13.7%) vs 5
(10.4%), p5 0.55; kidney problems 5 (2.7%) vs 3 (6.2%), p5 0.23;
neurological disorders 10 (5.5%) vs 1 (2.1%), p5 0.16; second neo-
plasm 3 (1.6%) vs 1 (2.1%), p5 0.83.
Conclusions: Majority of survivors after allogeneic HPCT de-
velop late sequelae. Patients transplanted with the diagnosis of ma-
lignant disease are at higher risk of cGvHD resulting in furthercomplications, mainly skin and ocular problems. Higher incidence
of cGvHD in this cohort of patients may be due to less intensive im-
munosupressive therapy in comparison to the subjects transplanted
due to non-malignant diseases. The impact of chemotherapy used
in the treatment of malignancies prior to HPCT should also be taken
into consideration. The multidisciplinary monitoring for a pro-
longed period of time after HPCT is strongly recommended.189
MUSCLE WEAKNESS FOLLOWING ALLOGENEIC STEM CELL TRANSPLAN-
TATION: ANALYSIS OF RISK FACTORS
Kiguchi, D.2, Nawa, Y.1, Nakase, K.1, Miyazaki, Y.1, Kohashi, S.1,
Kadohisa, S.1, Tauchi, H.2, Kogami, S.2, Hara, M.1 1Ehime Prefectural
Central Hospital, Matsuyama, Japan; 2Ehime Prefectural Central Hospi-
tal, Matsuyama, Japan
Allogeneic stem cell transplantation (allo-SCT) can cause severe
adversed effects, which is associated with functional impairment
and muscle weakness. In this study, we analyzed factors affecting
muscle weakness after allo-SCT in 21 patients (13 male, 8 female)
who had allo-SCT at Ehime Prefectural Central Hospital from April
2007–March 2009, Patient ages ranged from 26–64 (median 46
years) at the time of allo-SCT. Sixteen patients received stem cells
from unrelated donors, and 5 received them from related donors.
A myeloablative conditioning regimen was chosen for 14 patients,
and 7 patients had a reduced intensity conditioning regimen. The pa-
tients received lower extremity muscle training while muscle
strength was measured at the same time by a therapeutic exercise sys-
tem (Strength Ergo 240, Mitsubishi Electric Corp., Tokyo, Japan).
Percent changes of lower extremity muscle strength before allo-
SCT and 100 days after allo-SCT for each patient was calculated,
and muscle strength was also compared using the Mann-Whitney
U test between groups divided by various factors. The average per-
cent change of lower extremity muscle strength was
-22.16 24.3%, and age group (26-46 vs. 47-64 years), sex, and con-
ditioning regimens (myeloablative or non-myeloablative) did not
significantly affect muscle strength. Patients who had higher does
of steroids showed a tendency towards greater decreases in muscle
strength (high dose, -31.06 21.0% vs. low dose, -12.36 24.8%,
P5 0.057). Source of stem cells (unrelated, -28.86 24.0% vs. re-
lated, -0.56 6.1%, P5 0.026), grades of acute GVHD (grades 0-2,
-15.46 19.1% vs. grades 3-4 -62.26 1.1%, P\0.01), and levels of
serum albumin ($3.4 g/dl, -12.56 16.5% vs. \3.4 g/dl,
-34.86 28.0%, P5 0.047) significantly affected the decrease of mus-
cle strength. Our study suggests that muscle strength may be affected
by the source of stem cells, nutritious status and complications after
allo-SCT, and, patients at risk should receive more intensive therapy
to prevent loss of muscle strength after transplantation.190
A LONGITUDINAL COMPARISON OF QUALITY OF LIFE (QOL) IN PATIENTS
WITH MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (ALLOHCT) USING MYELOABLATIVE
(MY) OR REDUCED INTENSITY CONDITIONING (RIC)
Gupta, V.1, Li, L.2, Panzarella, T.2, Khan, J.1, Galal, A.1, Kuruvilla, J.1,
Lipton, J.1, Messner, H.1, Alibhai, S.3 1Princess Margaret Hospital, Tor-
onto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Canada;
3Toronto General Hospital, ON, Canada
There are limited data on the impact of intensity of conditioning
on QOL in patients undergoing alloHCT. We undertook a prospec-
tive study to evaluate the outcomes and QOL in patients with mye-
loid malignancies undergoing alloHCT using MY or RIC. 115
patients were enrolled from Jan 2005 to Sep 2008 and no significant
differences in the outcomes were observed in the two study cohorts at
1-year (abstract submitted separately).
Of 115 patients, 105 (91%) patients (MY, 44; RIC, 61) consented
to participate in QOL study with QOL assessments at baseline,
day30, day100, day180 and day365. QOL was assessed by the follow-
ing measures: European Organization for Research and Treatment
of Cancer core 30-item questionnaire (QLQ-C30), Functional As-
sessment of Cancer Therapy-bone marrow transplantation subscale
(FACT-BMT), FACT anaemia and fatigue subscale (FACT-An),
Poster Session I S229Hospital Anxiety and Depression Scale (HADS) and Lawton and
Brody’s instrumental activities of daily living.
Apart from age, both cohorts were well matched for baseline char-
acteristics. The median age of patients undergoing RIC was signifi-
cantly higher to those undergoing MY conditioning (59 vs. 42 yrs,
p\0.0001). The compliance for completion of QOL assessments
was: baseline, 98%; Day30, 91%; day100, 85%; day180, 84%; and
day365, 85%. The main reason for non-compliance was illness due
to toxicity or disease relapse.
QOL data were analyzed for both cohorts without imputation.
QOL scores did not differ for the two study groups at baseline.
There was a decline in QOL scores in post transplant period
with lowest scores at day30 followed by subsequent slow improve-
ment to baseline by day365. The RIC cohort had better QLQ-
C30 scores in the domains of physical functioning (p5 0.005)
and role functioning (p5 0.02) at day30. No other significant dif-
ferences were noted between the two groups at other time points.
Recovery post transplant was similar in the two cohorts. In a mul-
tivariate analysis, clinically meaningful differences in favor of RIC
cohort were observed in the role functioning domain of QLQ-
C30. In addition, patients with HCT-comorbidity scores$ 3
had significantly worse scores for emotional functioning and
global health domain of QLQC-30, FACT-BMT, FACT-An
and HADS.
Imputing QOL data using worst scores for patients who did not
complete QOL questionnaire due to illness did not significantly in-
fluence the above results.
We conclude that both MY and RIC regimens resulted in similar
QOL at 1-year post transplant.191
IMPLEMENTATION OF A HEMATOLOGICAL MALIGNANCY-BASED SURVI-
VORSHIP CLINIC
Asher, A., Steinberg, A. Cedars-Sinai Medical Center, Los Angeles, CA
Background: There are approximately 12 million cancer survivors
in the U.S. Cancer survivors are at increased risk for health compli-
cations such as heart disease, secondary malignancies, and psycho-
logical distress. Reflecting the needs of cancer survivors as part of
our health care system, the Institute of Medicine issued a seminal re-
port, From Cancer Patient to Cancer Survivor: Lost in Transition,
recognizing cancer survivorship as a ‘‘distinct phase of cancer
care.’’ A dedicated survivorship clinic with creation of personal
care plans and treatment summaries can serve the needs of this grow-
ing cohort of patients.
Objective: To determine the viability of a transplant/hematological
malignancy-based survivorship clinic with treatment summary and
care plan for survivors.
Methods: A literature search was initiated examining recommenda-
tions and guidelines regarding follow-up of cancer patients. We in-
corporated and consolidated guidelines from ASCO, NMDP,
NCCN, and COG, pertinent articles from the PubMed database,
and the growing literature for cancer survivorship. Awareness of
the program was to be initiated with letters to affiliated physicians,
lecture series, patient-oriented educational handouts, and articles
in the hospital literature.
Data Synthesis: A treatment care plan was devised for all survi-
vorship clinic patients. This care plan summarized patients’ prior
care with recommendations for follow-up such as cardiac and can-
cer screening, osteoporosis, thyroid disease, and vaccination
schedules–all based on our consolidative review of available evi-
dence-based or expert guidelines. A referral base was developed
with specialists focused on lymphedema, psychiatric issues (needs
determined by screening tools), social work, art therapy, exercise,
and nutrition.
Results: Patients from affiliated hematologists/oncologists were
seen in the survivorship clinic. Unique care plans were devised for
them based on their history of having had a hematologic malignancy
or a stem cell transplant. A satisfaction survey was to be imple-
mented. Preliminary satisfaction from both physicians and the pa-
tients themselves was positive.Conclusion: A transplant/hematologic malignancy-based survivor-
ship clinic is feasible and fills an important need in a large, urban,
hospital-based cancer center. Further investigation will focus on de-
veloping a computer-based treatment summary and care plan, in-
creasing patient referrals, and developing a lecture series devoted
to survivorship.192
OUTCOME OF SOLID ORGAN TRANSPLANT FOLLOWING BLOOD AND
MARROW TRANSPLANT (BMT) IN PEDIATRIC PATIENTS
Guzikowski, V., Bunin, N. Children’s Hospital of Philadelphia, PA
Blood and marrow transplant (BMT) may be curative for children
with malignancies as well as life-threatening non-malignant diseases.
However, permanent organ failure may result from conditioning
regimens or other BMT-related toxicities. Solid organ transplant
(SOT) may be indicated for a select group of pediatric patients,
but this poses difficult decisions for families and caregivers. There
is limited information available about the outcome of children who
received SOT following BMT. At the Children’s Hospital of Phila-
delphia, we have identified eight children (4 males) who have re-
ceived a solid organ transplant following a BMT. Patients (pts)
were 6 months to 18 years at the time of BMT. Diseases for which
BMT was indicated included: thalassemia, Wiskott-Adrich syn-
drome, Shwachman-Diamond/bone marrow failure, sickle cell dis-
ease (SCD), erythopoetic porphyria (EP), acute lymphoblastic
leukemia, chronic granulamotous disease, and neuroblastoma. BM
donors were matched sibling in 4, unrelated in 3, and autologous
for one. Time from BMT to SOT was 13 days-7 years (median, 27
months), with two pts\2 months who received liver transplants. In-
dications for liver transplant included VOD (2), chronic GVHD
(1).Lung SOT was performed for 2 pts with bronchiolitis obliterans
(2), and kidney transplants for 3 pts with renal failure. Three of the
organs were from a living related donor (2- liver, 1-kidney), and 5
were cadaveric organs. Four pts were on immunosuppressant agents
at the time of the SOT: 2 pts\2 months from BMT on a cyclospor-
ine infusion, one pt on tacrolimus for treatment of BOOP, and one pt
with EP on both azathioprine and prednisone due to a previous liver
transplant. Seven pts (2-lungs, 2-liver, 3-kidney) are alive with func-
tioning allografts two to 157 months from SOT. One pt with thalas-
semia developed multiple mesenteric artery thromboses following
two attempts at liver transplant and died. Advances in organ procure-
ment, operative technique, immunosuppressant therapy and infec-
tion control may allow SOT for a select group of pts post BMT.
However, scarcity of donor organs available in a timely fashion
continues to be a limiting factor. Children who have undergo
BMT and develop single organ failure should be considered for
a solid organ transplant if there is a high likelihood of cure of the
primary disease.193
FIRST DESCRIPTION OF A SUCCESSFUL PREGNANCY AFTERMYELOABLA-
TIVE STEM CELL TRANSPLANTATION IN A SICKLE CELL PATIENT BY
MEANS OF AN OVARIAN TISSUE AUTOGRAFT
Roux, C.1,5, Amiot, C.1,5, Agnani, G.2, Aubard, Y.3, Deconinck, E.4,5,
Piver, P.3, Rohrlich, P.S.4,5 1CHU Hopital Saint Jacques, Besancon,
France; 2CHU Hopital Saint Jacques, Besancon, France; 3CHU Hopital
Me`re et Enfant, Limoges, France; 4CHUHopital Jean Minjoz, Besancon,
France; 5UMR 645 INSERM/UFC/EFS BFC, Besancon, France
The preservation of fertility is an emerging concern in patients
treated by myeloablative hematopoietic stem cell transplantation
(HSCT). One major drawback of autologous gonadic tissue trans-
plant being the risk of leukemia recurrence, this procedure is first
to be proposed to patients allografted for non malignant diseases.
Cryopreservation of ovarian tissue with subsequent autotransplanta-
tion is an emerging procedure that has led to 6 reported births until
today, none of them being obtained after HSCT. Moreover, 3 of
these 6 pregnancies were obtained through in vitro fertilization pro-
cedures. We report the restoration of ovarian activity followed by
pregnancy and live birth after an orthotopic transplantation of ovar-
ian tissue in a 19 year old female patient transplanted for sickle cell
anemia. The patient having experienced a CNS stroke received an
